Group of Mycobacteriology, Unit of Medical Microbiology, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisbon, Portugal.
In Vivo. 2012 Mar-Apr;26(2):231-6.
Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.
耐多药结核病（MDRTB）在全球范围内的感染率持续上升，现已发展成为极端耐药结核病（XDRTB）。与 XDRTB 相比，MDRTB 相关的治疗问题相形见绌，因为 XDRTB 的死亡率很高。这篇小型综述强调了使用吩噻嗪类神经安定药硫利达嗪治疗 XDRTB 的证据。尽管硫利达嗪确实会产生一些严重的副作用，但对于患有 AIDS 的 XDRTB 感染者，由于预后不良，值得认真考虑使用硫利达嗪进行 XDRTB 治疗。本文提出了一个推荐的方案。
